Browse News
Filter News
Found 46,498 articles
-
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering - March 28, 2024
3/28/2024
Praxis Precision Medicines, Inc. announced the pricing of its underwritten public offering of 3,318,585 shares of its common stock at a public offering price per share of $56.50 and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 221,238 shares of common stock at a purchase price of $56.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant.
-
Sequana Medical announces 2023 Full Year Results and 2024 Outlook
3/28/2024
Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces its financial results for the year ended 31 December 2023, and provides a business update and outlook for 2024 and beyond.
-
Inventiva announces the nomination of Andre Turenne as Director
3/28/2024
Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis, also known as non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, announced the nomination of Andre Turenne to its Board of Directors.
-
Avenzo Therapeutics on Tuesday said it will use the financing round to advance its next-generation oncology pipeline, including a potentially best-in-class CDK2 selective inhibitor.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
3/27/2024
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) today announced a strategic pivot aimed at advancing its clinical-stage candidate stenoparib, a novel PARP/Tankyrase dual inhibitor, toward registration in advanced recurrent ovarian cancer, leveraging its DRP® platform to identify and enroll only the patients most likely to derive clinical benefit.
-
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
3/27/2024
Pyxis Oncology, Inc. announced that it has completed the sale of its rights to royalties from the commercialization of Beovu® and another asset to Novartis for a one-time cash payment of $8 million.
-
Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management
3/27/2024
Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, announced that it has entered into a Restructuring Support Agreement with certain funds managed by Highbridge Capital Management, LLC, the Company’s principal lender.
-
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
3/27/2024
Pieris Pharmaceuticals, Inc. provided a corporate update announcing a strategy to maximize its ability to capture the potential milestones from its 4-1BB bispecific Mabcalin® protein immuno-oncology assets partnered with Pfizer, Boston Pharmaceuticals, and Servier.
-
Praxis Precision Medicines, Inc. Announces Proposed Public Offering - March 27, 2024
3/27/2024
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock.
-
XORTX Announces New Clinical Advisory Board Member - March 27, 2024
3/27/2024
XORTX Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease, is pleased to announce that Dr. Ronald Perrone has joined the Company’s Clinical Advisory Board.
-
IDRx Appoints David P. Kerstein, M.D., as Chief Medical Officer
3/27/2024
IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, announced the appointment of David P. Kerstein, M.D., as Chief Medical Officer.
-
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
3/27/2024
Inhibikase Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted recent developments.
-
Sanyou Bio: Sanyou's Intelligence-Enabled Innovative Biologics R&D Platform Leads in the New Era of Biological Drug Development
3/27/2024
Dr. Guojun Lang, founder and CEO of Sanyou Biopharmaceuticals provides industry insights.
-
Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update
3/27/2024
Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.
-
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
3/27/2024
Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.
-
Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting
3/27/2024
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced fifteen podium and four poster presentations during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which will take place in Boston, April 5-8, 2024.
-
Boundless Bio Announces Pricing of Initial Public Offering
3/27/2024
Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of $16.00 per share.
-
Egle Therapeutics Strengthens its Leadership Team with the Appointment of Monica Gostissa, PhD, as Chief Scientific Officer and Reno Winter, PhD, as Chief Technical Officer
3/27/2024
Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Monica Gostissa, PhD, as Chief Scientific Officer and Reno Winter, PhD, as Chief Technical Officer.
-
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
3/27/2024
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.